相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current Treatment Concepts of Philadelphia-Negative MPN
D. Wolf et al.
CURRENT CANCER DRUG TARGETS (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Fabio P. S. Santos et al.
BLOOD (2010)
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
Priya Koppikar et al.
BLOOD (2010)
Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis
Srdan Verstovsek
CLINICAL CANCER RESEARCH (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Gerlinde Werning et al.
CANCER CELL (2008)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Virginia M. Zaleskas et al.
PLOS ONE (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
F Ding et al.
BLOOD (2004)
Intracellular phospho-protein staining techniques for flow cytometry: Monitoring single cell signaling events
PO Krutzik et al.
CYTOMETRY PART A (2003)
分享论文
